期刊文献+
共找到108篇文章
< 1 2 6 >
每页显示 20 50 100
Gut microbiota-derived metabolites are novel targets for improving insulin resistance 被引量:2
1
作者 Rosana MC Bastos Érika B Rangel 《World Journal of Diabetes》 SCIE 2022年第1期65-69,共5页
The gut microbiota plays a key role in metabolic diseases.Gut-microbiota-derived metabolites are found in different dietary sources,including:Carbohydrate(acetate,propionate,butyrate,also known as short-chain fatty ac... The gut microbiota plays a key role in metabolic diseases.Gut-microbiota-derived metabolites are found in different dietary sources,including:Carbohydrate(acetate,propionate,butyrate,also known as short-chain fatty acids,as well as succinate);protein(hydrogen sulfide,indole,and phenylacetic acid);and lipids(resveratrol-,ferulic acid-,linoleic acid-,catechin-and berry-derived metabolites).Insulin resistance,which is a global pandemic metabolic disease that progresses to type 2 diabetes mellitus,can be directly targeted by these metabolites.Gutmicrobiota-derived metabolites have broad effects locally and in distinct organs,in particular skeletal muscle,adipose tissue,and liver.These metabolites can modulate glucose metabolism,including the increase in glucose uptake and lipid oxidation in skeletal muscle,and decrease in lipogenesis and gluconeogenesis associated with lipid oxidation in the liver through activation of phosphatidylinositol 3-kinase-serine/threonine-protein kinase B and AMP-activated protein kinase.In adipose tissue,gut-microbiota-derived metabolites stimulate adipogenesis and thermogenesis,inhibit lipolysis,and attenuate inflammation.Importantly,an increase in energy expenditure and fat oxidation occurs in the whole body.Therefore,the therapeutic potential of current pharmacological and non-pharmacological approaches used to treat diabetes mellitus can be tested to target specific metabolites derived from intestinal bacteria,which may ultimately ameliorate the hyperglycemic burden. 展开更多
关键词 Insulin resistance Gut microbiota METABOLITES Host metabolism Metabolic organs novel targets
下载PDF
Cardiac hybrid imaging: novel tracers for novel targets 被引量:1
2
作者 Andrea Ponsiglione Raffaele Ascione +5 位作者 Carmela Nappi Massimo Imbriaco Michele Klain Renato Cuocolo Alberto Cuocolo Mario Petretta 《Journal of Geriatric Cardiology》 SCIE CAS CSCD 2021年第9期748-758,共11页
Non-invasive cardiac imaging has explored enormous advances in the last few decades.In particular,hybrid imaging represents the fusion of information from multiple imaging modalities,allowing to provide a more compreh... Non-invasive cardiac imaging has explored enormous advances in the last few decades.In particular,hybrid imaging represents the fusion of information from multiple imaging modalities,allowing to provide a more comprehensive dataset compared to traditional imaging techniques in patients with cardiovascular diseases.The complementary anatomical,functional and molecular information provided by hybrid systems are able to simplify the evaluation procedure of various pathologies in a routine clinical setting.The diagnostic capability of hybrid imaging modalities can be further enhanced by introducing novel and specific imaging biomarkers.The aim of this review is to cover the most recent advancements in radiotracers development for SPECT/CT,PET/CT,and PET/MRI for cardiovascular diseases. 展开更多
关键词 PET novel tracers for novel targets Cardiac hybrid imaging
下载PDF
Fatty acid binding protein 5 is a novel therapeutic target for hepatocellular carcinoma
3
作者 Yan Li William Lee +3 位作者 Zhen-Gang Zhao Yi Liu Hao Cui Hao-Yu Wang 《World Journal of Clinical Oncology》 2024年第1期130-144,共15页
BACKGROUND Hepatocellular carcinoma(HCC)is an aggressive subtype of liver cancer and is one of the most common cancers with high mortality worldwide.Reprogrammed lipid metabolism plays crucial roles in HCC cancer cell... BACKGROUND Hepatocellular carcinoma(HCC)is an aggressive subtype of liver cancer and is one of the most common cancers with high mortality worldwide.Reprogrammed lipid metabolism plays crucial roles in HCC cancer cell survival,growth,and evolution.Emerging evidence suggests the importance of fatty acid binding proteins(FABPs)in contribution to cancer progression and metastasis;however,how these FABPs are dysregulated in cancer cells,especially in HCC,and the roles of FABPs in cancer progression have not been well defined.AIM To understand the genetic alterations and expression of FABPs and their associated cancer hallmarks and oncogenes in contributing to cancer malignancies.METHODS We used The Cancer Genome Atlas datasets of pan cancer and liver hepatocellular carcinoma(LIHC)as well as patient cohorts with other cancer types in this study.We investigated genetic alterations of FABPs in various cancer types.mRNA expression was used to determine if FABPs are abnormally expressed in tumor tissues compared to non-tumor controls and to investigate whether their expression correlates with patient clinical outcome,enriched cancer hallmarks and oncogenes previously reported for patients with HCC.We determined the protein levels of FABP5 and its correlated genes in two HCC cell lines and assessed the potential of FABP5 inhibition in treating HCC cells.RESULTS We discovered that a gene cluster including five FABP family members(FABP4,FABP5,FABP8,FABP9 and FABP12)is frequently co-amplified in cancer.Amplification,in fact,is the most common genetic alteration for FABPs,leading to overexpression of FABPs.FABP5 showed the greatest differential mRNA expression comparing tumor with non-tumor tissues.High FABP5 expression correlates well with worse patient outcomes(P<0.05).FABP5 expression highly correlates with enrichment of G2M checkpoint(r=0.33,P=1.1e-10),TP53 signaling pathway(r=0.22,P=1.7e-5)and many genes in the gene sets such as CDK1(r=0.56,P=0),CDK4(r=0.49,P=0),and TP53(r=0.22,P=1.6e-5).Furthermore,FABP5 also correlates well with two co-expressed oncogenes PLK1 and BIRC5 in pan cancer especially in LIHC patients(r=0.58,P=0;r=0.58,P=0;respectively).FABP5high Huh7 cells also expressed higher protein levels of p53,BIRC5,CDK1,CDK2,and CDK4 than FABP5low HepG2 cells.FABP5 inhibition more potently inhibited the tumor cell growth in Huh7 cells than in HepG2 cells.CONCLUSION We discovered that FABP5 gene is frequently amplified in cancer,especially in HCC,leading to its significant elevated expression in HCC.Its high expression correlates well with worse patient outcome,enriched cancer hallmarks and oncogenes in HCC.FABP5 inhibition impaired the cell viability of FABP5high Huh7 cells.All these support that FABP5 is a novel therapeutic target for treating FABP5high HCC. 展开更多
关键词 Hepatocellular carcinoma Fatty acid binding protein novel target AMPLIFICATION Correlated expression
下载PDF
Oxidized low-density lipoprotein receptor 1:a novel potential therapeutic target for intracerebral hemorrhage 被引量:3
4
作者 Hui-Yuan Zhang Xi Lu +2 位作者 Yue-Han Hao Ling Tang Zhi-Yi He 《Neural Regeneration Research》 SCIE CAS CSCD 2022年第8期1795-1801,共7页
Oxidized low-density lipoprotein receptor 1(OLR1)is upregulated in neurons and participates in hypertension-induced neuronal apoptosis.OLR1 deletion exerts protective effects on cerebral damage induced by hypertensive... Oxidized low-density lipoprotein receptor 1(OLR1)is upregulated in neurons and participates in hypertension-induced neuronal apoptosis.OLR1 deletion exerts protective effects on cerebral damage induced by hypertensive-induced stroke.Therefore,OLR1 is likely involved in the progress of intracerebral hemorrhage.In this study,we examined the potential role of OLR1 in intracerebral hemorrhage using a rat model.OLR1 small interfering RNA(10μL;50 pmol/μL)was injected into the right basal ganglia to knock down OLR1.Twenty-four hours later,0.5 U collagenase type VII was injected to induce intracerebral hemorrhage.We found that knockdown of OLR1 attenuated neurological behavior impairment in rats with intracerebral hemorrhage and reduced hematoma,neuron loss,inflammatory reaction,and oxidative stress in rat brain tissue.We also found that silencing of OLR1 suppressed ferroptosis induced by intracerebral hemorrhage and the p38 signaling pathway.Therefore,silencing OLR1 exhibits protective effects against secondary injury of intracerebral hemorrhage.These findings suggest that OLR1 may be a novel potential therapeutic target for intracerebral hemorrhage. 展开更多
关键词 ferroptosis inflammation intracerebral hemorrhage neurological behavior NEUROPROTECTION novel therapeutic target oxidative stress oxidized low-density lipoprotein receptor 1 p38 signaling pathway secondary brain injury
下载PDF
Astrocytic Kir4.1 potassium channels as a novel therapeutic target for epilepsy and mood disorders 被引量:5
5
作者 Yukihiro Ohno 《Neural Regeneration Research》 SCIE CAS CSCD 2018年第4期651-652,共2页
Astrocytic Kir4.1 channels and spatial potassium buffering:Astrocytes play a crucial role in maintaining the structural and functional integrity of the brain,which includes formation of the blood-brain barrier,mainte... Astrocytic Kir4.1 channels and spatial potassium buffering:Astrocytes play a crucial role in maintaining the structural and functional integrity of the brain,which includes formation of the blood-brain barrier,maintenance of water and ion homeostasis,metabolism of neurotransmitters and secretion of various neuroactive molecules. 展开更多
关键词 Astrocytic Kir4.1 potassium channels as a novel therapeutic target for epilepsy and mood disorders FIGURE
下载PDF
Substance P and its tachykinin NK1 receptor: a novel neuroprotective target for Parkinson's disease 被引量:3
6
作者 Emma Thornton Robert Vink 《Neural Regeneration Research》 SCIE CAS CSCD 2015年第9期1403-1405,共3页
Parkinson's disease (PD) is the most common motor neurode- generative disorder affecting approximately 4 million people worldwide. Although PD presents primarily with motor dysfunction, non-motor symptoms including... Parkinson's disease (PD) is the most common motor neurode- generative disorder affecting approximately 4 million people worldwide. Although PD presents primarily with motor dysfunction, non-motor symptoms including cognitive decline, mood disorders, reduced olfaction and constipation are also of- ten present, with some of these non-motor symptoms even pre- senting prior to the onset of motor symptoms. It is well known that PD is largely caused by the gradual degeneration of dopa- minergic neurons within the substantia nigra pars compacta (SNc), along with the presence of protein aggregates called Lewy bodies, which consist primarily of ct-synuclein and are found in the cytoplasm of surviving neurons. This ongoing cell loss and Lewy body pathology is not confined to the SNc, but is also seen in other brain regions implicated in PD pathogenesis such as the locus ceruleus. 展开更多
关键词 NK a novel neuroprotective target for Parkinson’s disease Substance P and its tachykinin NK1 receptor
下载PDF
构建SLE患者novel microRNA差异性表达谱及其靶基因的功能分析
7
作者 陈文标 戴勇 +5 位作者 钟馨 叶素惠 何桂芳 缪蕙 丘衍博 李朝辉 《西安交通大学学报(医学版)》 CAS CSCD 北大核心 2015年第2期225-230,共6页
目的构建系统性红斑狼疮(SLE)患者与健康对照者(NC)新小核糖核酸(novel microRNA)的差异性表达谱;对显著性差异表达的novel microRNA进行靶基因预测,对靶基因的GO(gene ontology)及KEGG(kyoto encyclopedia of genes and genomes)的功... 目的构建系统性红斑狼疮(SLE)患者与健康对照者(NC)新小核糖核酸(novel microRNA)的差异性表达谱;对显著性差异表达的novel microRNA进行靶基因预测,对靶基因的GO(gene ontology)及KEGG(kyoto encyclopedia of genes and genomes)的功能进行分析,探讨SLE的发病机制。方法运用高通量测序技术(high-throughput sequencing)获得SLE与NC总的RNA,对总RNA进行长度分布、基因比对、RNA分类注释、RNA特有及公共序列统计后,运用Mireap软件预测novel microRNA。得到novel microRNA进行差异性表达分析,寻找两组之间具有显著性表达的novel microRNA。采用Targetscan软件对差异性表达的novel microRNA进行靶基因预测,并选取靶基因借用DAVID功能注释软件对其参与的生物学过程进行GO富集及KEGG通路分析。结果 61个novel microRNAs在SLE与NC组之间具有显著差异性表达,其中43个上调表达,18个下调表达。差异性表达novel microRNA的靶基因主要富集在细胞与小分子结合、细胞器官与细胞膜、细胞代谢中。靶基因KEGG通路主要体现在粘附复合体通路中。结论 SLE与NC的novel microRNA存在差异性表达。差异性表达novel microRNA的靶基因可能在SLE的发病机制与临床症状中起着重要作用,可能作为特异性靶点深入研究。 展开更多
关键词 系统性红斑狼疮 新小核糖核酸 靶基因 差异性表达 GO富集 KEGG通路
下载PDF
Meta-analysis of gemcitabine plus nab-paclitaxel combined with targeted agents in the treatment of metastatic pancreatic cancer
8
作者 Zhong-Hui Li Yin-Jie Ma +4 位作者 Zong-Hang Jia Yue-Yan Weng Ping Zhang Shi-Jie Zhu Fang Wang 《World Journal of Clinical Cases》 SCIE 2022年第27期9703-9713,共11页
BACKGROUND Gemcitabine plus nab-paclitaxel(GA) is a commonly used first-line treatment regimen for metastatic pancreatic cancer,and many studies will add a novel targeted agent to this regimen for improving patient su... BACKGROUND Gemcitabine plus nab-paclitaxel(GA) is a commonly used first-line treatment regimen for metastatic pancreatic cancer,and many studies will add a novel targeted agent to this regimen for improving patient survival rate.However,the clinical effectiveness of GA is the most controversial issue.AIM To compare the efficacy and safety of GA regimen with a targeted agent and GA regimen.METHODS Up to 1 December 2021,the eligible randomized controlled trials(RCTs) relating to GA and GA with a targeted agent were searched on Pub Med,EMBASE and Cochrane Library for eligible data.We screened out appropriate studies for overall survival(OS),progression-free survival(PFS),objective response rate(ORR),and toxicity,which had been pooled and finally analyzed by using Stata version 15.1.In addition,we use Reference Citation Analysis(https://www.referencecitationanalysis.com/) to collect the latest related literature to improve the latest cutting-edge research results.RESULTS Seven RCTs involving 1544 patients(848 men and 696 women) were included.There were no significant differences between GA with a targeted agent and GA in PFS [hazard ratio(HR):1.18 95% confidence interval(CI):0.91-1.53],OS(HR:1.12 95%CI:0.99-1.27),and ORR(HR:0.96 95%CI:0.71-1.29).There was no notable difference in the two groups in grade 3/4 toxicity(fatigue,anemia,vomiting and neutropenia),whereas the incidence of grade 3/4 diarrhea considerably increased in GA with a targeted drug.CONCLUSION Adding a novel targeted agent to the GA regimen did not improve survival rate of patients with metastatic pancreatic cancer. 展开更多
关键词 Metastatic pancreatic cancer GEMCITABINE NAB-PACLITAXEL novel targeted agent SURVIVAL
下载PDF
家蚕miRNA Novel-31*上调溶血素基因的表达 被引量:1
9
作者 施莉莉 耿涛 +5 位作者 吴萍 潘中华 覃光星 高坤 侯成香 郭锡杰 《昆虫学报》 CAS CSCD 北大核心 2016年第7期724-731,共8页
【目的】Novel-31*是在家蚕质型多角体病毒(Bombyx mori cytoplasmic polyhedrosis virus,Bm CPV)感染的家蚕中发现的一个差异表达miRNA。本研究旨在验证Novel-31*对其靶基因表达的调控作用,以便进一步研究miRNA及其靶基因在昆虫免疫调... 【目的】Novel-31*是在家蚕质型多角体病毒(Bombyx mori cytoplasmic polyhedrosis virus,Bm CPV)感染的家蚕中发现的一个差异表达miRNA。本研究旨在验证Novel-31*对其靶基因表达的调控作用,以便进一步研究miRNA及其靶基因在昆虫免疫调节中的作用。【方法】用生物信息学方法预测Novel-31*的靶基因,荧光定量PCR分析Novel-31*及其靶基因在家蚕感染Bm CPV后不同时间点的表达变化;构建miRNA慢病毒表达载体和靶基因慢病毒表达载体,转染293T细胞,同时合成Novel-31*mimics转染家蚕培养细胞Bm N,使用荧光定量PCR检测Novel-31*对靶基因表达的调控作用。【结果】生物信息学方法预测发现,溶血素基因是Novel-31*的靶基因,其结合位点位于溶血素基因的5'UTR区域。荧光定量PCR分析表明,Novel-31*及溶血素基因在感染Bm CPV的家蚕血淋巴细胞中呈现明显的上调表达。荧光定量PCR检测表明,在Novel-31*慢病毒表达载体和溶血素基因5'UTR慢病毒表达载体转染的293T细胞中和在转染Novel-31*mimics的家蚕Bm N细胞中,溶血素基因都上调表达。【结论】溶血素基因是miRNA Novel-31*的靶基因,Novel-31*与溶血素基因5'UTR结合,上调溶血素基因的表达。 展开更多
关键词 家蚕 MIRNA novel-31* 靶基因 慢病毒载体 溶血素
下载PDF
水牛Novel-miR-57对Bcap-37和BMECs细胞DOK4基因的调控作用 被引量:2
10
作者 蔡小艳 李雅辉 +6 位作者 鲍正潘 陈秋萍 李胜 周宇 邓凯 石德顺 刘庆友 《南方农业学报》 CAS CSCD 北大核心 2021年第2期269-279,共11页
【目的】筛选Novel-miR-57调控靶基因,并明确其对靶基因的调控作用及生物功能,为揭示水牛乳腺上皮细胞(BMECs)的分化机理提供科学依据。【方法】利用MiRscan预测Novel-miR-57二级结构;以自编软件Ensembl(v80)注释的水牛mRNA截取3'-... 【目的】筛选Novel-miR-57调控靶基因,并明确其对靶基因的调控作用及生物功能,为揭示水牛乳腺上皮细胞(BMECs)的分化机理提供科学依据。【方法】利用MiRscan预测Novel-miR-57二级结构;以自编软件Ensembl(v80)注释的水牛mRNA截取3'-非翻译区(3'-UTR)作为预测数据库,采用Miranda(v3.3a)对Novel-miR-57进行靶基因预测;运用实时荧光定量PCR筛选重点靶基因。以化学合成的Novel-miR-57模拟物Mimics和抑制剂Inhibitor,分别转染人类乳腺癌细胞(Bcap-37)及BMECs细胞,以验证Novel-miR-57与靶基因的表达相关性。【结果】Novel-miR-57前体序列形成7个茎环结构,成熟序列位于第1、2和3个茎环结构间,其结合自由能为-53.70 kcal/mol。以结合自由能低于-20.00 kcal/mol为标准,最终筛选出34个可能的靶基因,共与42条KEGG信号通路存在关联,其富集的信号通路主要有代谢通路(ID:bta01100)、PI3K-Akt信号通路(ID:bta04151)、MAPK信号通路(ID:bta04010)和细胞因子—细胞因子受体相互作用(ID:bta04060)等;经实时荧光定量PCR检测分析发现DLX3、CANCNG3、DOK4、NFKBID、C17orf53、RTN1和FBXO10等7个靶基因在非泌乳期的相对表达量极显著高于泌乳期(P<0.01),二者间相差100.0倍以上,且与NovelmiR-57的相对表达量呈负相关。7个靶基因中仅DOK4基因与Novel-miR-57的表达具相关性,以200 nmol/L Inhibitor转染B-cap37细胞能显著提高DOK4基因表达(P<0.05,下同),添加100 nmol/L Mimics则显著抑制DOK4基因表达。以100 nmol/L Mimics转染BMECs细胞,Novel-miR-57和DOK4基因的相对表达量显著提高;而以200 nmol/L Inhibitor转染BMECs细胞,Novel-miR-57和DOK4基因的表达均受到显著抑制。【结论】Novel-miR-57含有7个茎环结构,且其成熟序列位于第1~3个茎环上。Novel-miR-57过表达可下调Bcap-37细胞DOK4基因表达或上调BMECs细胞DOK4基因表达,即Novel-miR-57对靶基因的调控作用因乳腺细胞生理状态不同而存在差异。 展开更多
关键词 水牛 novel-miR-57 靶基因 BMECs细胞 Bcap-37细胞 调控作用
下载PDF
A Comparative Study of William Golding's Four Novels
11
作者 崔晓强 《科技信息》 2008年第36期287-290,共4页
With his keen insight,William Golding becomes very conscious of the darkness of the human heart and the necessity that we become aware of this darkness if we are to save ourselves. All his novels,therefore,attempt to ... With his keen insight,William Golding becomes very conscious of the darkness of the human heart and the necessity that we become aware of this darkness if we are to save ourselves. All his novels,therefore,attempt to deal with the essential human condition. All Golding's novels,products of his peculiar literary temperament and habit,are reactive experiments. Each of them represents a response to a specific book by an early writer. 展开更多
关键词 小说 文学作品 英语 文学评论
下载PDF
The role of histamine H4 receptors as a potential targets in allergic rhinitis and asthma 被引量:1
12
作者 Eva Hanuskova Jana Plevkova 《Open Journal of Molecular and Integrative Physiology》 2013年第1期6-14,共9页
Histamine—the main product of mast cells plays critical role in the pathogenetic pathways of both allergic rhinitis and asthma. The novel concept of the unique airway diseases its only supported by the similarities w... Histamine—the main product of mast cells plays critical role in the pathogenetic pathways of both allergic rhinitis and asthma. The novel concept of the unique airway diseases its only supported by the similarities within pathogenetic process. Antagonists of H1 and H2 receptors are quite effective in allergic rhinitis, but not effective enough in asthma. In an era of corticosteroids, leucotriene antagonists and Anti-IgE treatment, there is still a challenge to search for more effective, more acurate and more safe treatment option. Antagonists (inversive agonists) of histamine receptors H4 seems to be one of the promising targets in the allergic rhinitis and asthma treatment. The first H4 antagonist entered to clinics and the results from a proof-of-concept Phase II clinical study is expected to be disclosed soon. This review article summarizes current knowledge on H4R that have been collected in various studies sharing evidences about efficacy of H4R as a reasonable target for diseases with histamine involved pathogenetic pathways. 展开更多
关键词 ALLERGIC Rhinits ASTHMA HISTAMINE H4R novel DRUG target
下载PDF
Novel therapy for advanced gastric cancer
13
作者 Yue Zhang Shenhong Wu 《World Journal of Gastrointestinal Oncology》 SCIE CAS 2015年第11期263-270,共8页
Gastric cancer(GC) is a common lethal malignancy.Gastroesophageal junction and gastric cardia tumors are the fastest rising malignancies due to increasing prevalence of obesity and acid reflex in the United States.Tra... Gastric cancer(GC) is a common lethal malignancy.Gastroesophageal junction and gastric cardia tumors are the fastest rising malignancies due to increasing prevalence of obesity and acid reflex in the United States.Traditional chemotherapy remains the main treatment with trastuzumab targeting human epidermal growth factor receptor 2 positive disease.The median overall survival(OS) is less than one year for advanced GC patients; thus,there is an urgent unmet need to develop novel therapy for GC.Although multiple targeted agents were studied,only the vascular endothelial growth factor receptor inhibitor ramucirumab was approved recently by the United States Food and Drug Administration because of its 1.4 mo OS benefit(5.2 mo vs 3.8 mo,P = 0.047) as a single agent; 2.2 mo improvement of survival(9.6 mo vs 7.4 mo,P = 0.017) when combined with paclitaxel in previously treated advanced GC patients.It is the first single agent approved for previously treated GC and the second biologic agent after trastuzumab.Even with limited success,targeted therapy may be improved by developing new biomarkers.Immune therapy is changing the paradigm of cancer treatment and is presently under active investigation for GC in clinical trials.More evidence supports GC stem cells existence and early stage studies are looking for its potential therapeutic possibilities. 展开更多
关键词 GASTRIC CANCER novel THERAPY targetED THERAPY Immu
下载PDF
Present and future of metastatic colorectal cancer treatment: A review of new candidate targets 被引量:7
14
作者 Giulia Martini Teresa Troiani +11 位作者 Claudia Cardone Pietropaolo Vitiello Vincenzo Sforza Davide Ciardiello Stefania Napolitano Carminia Maria Della Corte Floriana Morgillo Antonio Raucci Antonio Cuomo Francesco Selvaggi Fortunato Ciardiello Erika Martinelli 《World Journal of Gastroenterology》 SCIE CAS 2017年第26期4675-4688,共14页
In the last two decades, great efforts have been made in the treatment of metastatic colorectal cancer(m CRC) due to the approval of new target agents for cytotoxic drugs. Unfortunately, a large percentage of patients... In the last two decades, great efforts have been made in the treatment of metastatic colorectal cancer(m CRC) due to the approval of new target agents for cytotoxic drugs. Unfortunately, a large percentage of patients present with metastasis at the time of diagnosis or relapse after a few months. The complex molecular heterogeneity of this disease is not completely understood; to date, there is a lack of predictive biomarkers that can be used to select subsets of patients who may respond to target drugs. Only the RAS-mutation status is used to predict resistance to anti-epidermal growth factor receptor agents in patients with m CRC. In this review, we describe approved targeted therapies for the management of metastatic m CRC and discuss new candidate targets on the horizon. 展开更多
关键词 新奇 biomarkers Monoclonal 抗体 抵抗 变化 地岬 目标治疗 变形 colorectal 癌症
下载PDF
高粱低氮胁迫相关novel-miRNA的鉴定及其靶基因预测
15
作者 马建华 杨艳君 +2 位作者 赵红梅 冯玉杰 罗爱国 《应用与环境生物学报》 CAS CSCD 北大核心 2024年第2期377-384,共8页
为探究microRNA(miRNA)在高粱低氮胁迫反应中的调控作用,对高粱幼苗进行短时(8 h)和长时(15 d)低氮胁迫处理,采用Illumina HiSeqTM2000对其小RNA进行高通量测序,利用mireap软件预测novel-miRNA,分析其表达差异性.对差异表达的miRNA进行... 为探究microRNA(miRNA)在高粱低氮胁迫反应中的调控作用,对高粱幼苗进行短时(8 h)和长时(15 d)低氮胁迫处理,采用Illumina HiSeqTM2000对其小RNA进行高通量测序,利用mireap软件预测novel-miRNA,分析其表达差异性.对差异表达的miRNA进行表达模式聚类分析及茎环RT-PCR荧光定量验证.采用TargetFinder软件对差异表达的novel-miRNA进行靶基因预测,并对预测的靶基因进行Gene Ontology(GO)注释分类.结果显示:123个novel-miRNAs中,有40个novel-miRNAs具有显著或极显著表达差异.根系中,短时胁迫下有6个为上调表达,10个下调表达,长时胁迫时,上调和下调表达数各3个;叶片中,短时胁迫4个为上调表达,22为下调表达,长时胁迫上调和下调表达数分别为2个和9个.这些差异表达的novel-miRNAs在根系和叶片中的表达模式不同,分别聚为Ⅰ、Ⅱ、Ⅲ三种类型.它们不均等分布在不同染色体上,2号染色体上分布最多,其次为4号、1号和7号染色体.novel-miRNAs预测到8个靶基因,这些靶基因涉及物质代谢、刺激反应、生物调控、生殖发育等多个生命过程.本研究从高粱中鉴定了40个低氮胁迫差异表达的novel-miRNAs,预测到8个靶基因,结果为高粱低氮胁迫调控机制研究提供相关miRNAs及优良候选基因.(图7表3参36) 展开更多
关键词 高粱 低氮胁迫 novel-miRNA 靶基因
原文传递
仝小林态靶辨治新型冠状病毒感染后遗四肢肌痛1例 被引量:1
16
作者 陈科宇 高泽正 +11 位作者 周丹妮 张湘苑 孙阿茹 孙郡 薛崇祥 廖春燕 雷烨 李修洋 王涵 杨映映 李青伟 罗建江 《吉林中医药》 2023年第9期1084-1087,共4页
报告态靶结合治疗新疆新型冠状病毒感染后遗四肢肌痛患者1例。通过对该患者诊疗过程的回顾分析,在仝小林对新型冠状病毒感染郁、闭、脱、虚不同阶段认识的基础上,认为新型冠状病毒感染引起的肌痛属于病毒感染引起的自身免疫性肌炎,目前... 报告态靶结合治疗新疆新型冠状病毒感染后遗四肢肌痛患者1例。通过对该患者诊疗过程的回顾分析,在仝小林对新型冠状病毒感染郁、闭、脱、虚不同阶段认识的基础上,认为新型冠状病毒感染引起的肌痛属于病毒感染引起的自身免疫性肌炎,目前临床报道较少,通过态靶辨治思路组方,明显改善了患者因自身免疫导致的肌痛症状,以期为临床诊治此类患者提供借鉴思路。 展开更多
关键词 仝小林 态靶辨治 新型冠状病毒感染 肌痛 自身免疫 五体痹
下载PDF
慢性肾脏病微炎症反应新型治疗靶点研究进展
17
作者 王诗涵 王顺 《临床肾脏病杂志》 2023年第9期764-768,共5页
随着时代的发展与科学的进步,人们对健康的需求及生活质量的提高日益增加,近年慢性肾脏病(chronic kidney disease,CKD)的发生发展已成为社会各界关注的热点话题,CKD患者体内长期伴随轻微且持续的炎症状态,而这一状态又进一步导致CKD病... 随着时代的发展与科学的进步,人们对健康的需求及生活质量的提高日益增加,近年慢性肾脏病(chronic kidney disease,CKD)的发生发展已成为社会各界关注的热点话题,CKD患者体内长期伴随轻微且持续的炎症状态,而这一状态又进一步导致CKD病情进展。临床上针对CKD患者微炎症反应目前尚无明确统一的治疗方案,本文基于近期实验及临床研究,针对微炎症反应路径,减缓肾脏功能减退的新型治疗靶点的最新进展做一梳理和总结,以期能为CKD患者微炎症反应靶点治疗提供新的临床思路。 展开更多
关键词 慢性肾脏病 微炎症反应 新型治疗靶点
下载PDF
精准医学时代治疗外周T细胞淋巴瘤的新型药物研究进展
18
作者 周晓丽 胡顺凤 王欣 《山东第一医科大学(山东省医学科学院)学报》 CAS 2023年第1期1-9,共9页
外周T细胞淋巴瘤(peripheral T-cell lymphoma,PTCL)具有恶性程度高、分子异质性强、临床预后极差等特点。由于缺乏对PTCL病因及发病机制的认识,一线治疗进展长期停滞,PTCL患者的五年总生存率不足30%,临床诊疗面临巨大挑战。精准医学概... 外周T细胞淋巴瘤(peripheral T-cell lymphoma,PTCL)具有恶性程度高、分子异质性强、临床预后极差等特点。由于缺乏对PTCL病因及发病机制的认识,一线治疗进展长期停滞,PTCL患者的五年总生存率不足30%,临床诊疗面临巨大挑战。精准医学概念的提出及高通量多组学测序的发展推动了分子靶点的发现和药物的研发,多种新型药物在PTCL的临床治疗中展现出较好的抗肿瘤效果及耐受性,包括二氢叶酸还原酶抑制剂、组蛋白去乙酰化酶抑制剂、单克隆抗体及抗体偶联药物、信号通路抑制剂等。本文就精准医学时代下PTCL临床治疗中新型药物的研究进展进行综述。 展开更多
关键词 外周T细胞淋巴瘤 精准医学 新型药物 靶向干预
下载PDF
84例新型抗肿瘤药品不良反应报告分析 被引量:1
19
作者 杨岩 周德喜 +4 位作者 吴欣俐 薛淑雅 丁海华 张泉 张云玲 《中国药物警戒》 2023年第3期334-338,共5页
目的研究我院新型抗肿瘤药物引起的药品不良反应(adverse drug reaction,ADR)发生特点及规律,为临床合理用药提供参考。方法收集我院2020年1月1日至2021年12月31日上报至国家药品不良反应监测系统的新型抗肿瘤药物ADR,对ADR类型、患者... 目的研究我院新型抗肿瘤药物引起的药品不良反应(adverse drug reaction,ADR)发生特点及规律,为临床合理用药提供参考。方法收集我院2020年1月1日至2021年12月31日上报至国家药品不良反应监测系统的新型抗肿瘤药物ADR,对ADR类型、患者年龄和疾病类型、药品种类、累及系统-器官、严重ADR的主要药品及临床表现等方面进行分析。结果84例新型抗肿瘤药物ADR中,中老年患者居多;累及系统-器官主要是消化系统和皮肤及其附件系统;严重ADR占比34.52%。9例患者存在超说明书用药的问题。结论临床医师和药师应重视新型抗肿瘤药物致ADR,加强患者药学监护,为临床用药安全以及药品上市后再评价提供参考依据。 展开更多
关键词 药品不良反应 新型抗肿瘤药 靶向药物 免疫检查点抑制剂 药学监护
下载PDF
压缩空气储能工程现状、发展趋势及应用展望 被引量:3
20
作者 刘笑驰 梅生伟 +5 位作者 丁若晨 钟声远 张险峰 谢宁宁 常勇 张通 《电力自动化设备》 EI CSCD 北大核心 2023年第10期38-47,102,共11页
压缩空气储能(CAES)是一种大规模物理储能技术,可广泛应用于电网削峰填谷和大规模新能源消纳。当前我国CAES正处于由示范项目向产业化发展的关键阶段,呈现出良好的发展态势。系统总结了国内外CAES工程现状,介绍了已投运的商业电站,并对... 压缩空气储能(CAES)是一种大规模物理储能技术,可广泛应用于电网削峰填谷和大规模新能源消纳。当前我国CAES正处于由示范项目向产业化发展的关键阶段,呈现出良好的发展态势。系统总结了国内外CAES工程现状,介绍了已投运的商业电站,并对其在新能源侧的应用前景进行了阐述。进一步,从装机规模、系统效率、应用场景、建设成本等多个方面对其发展趋势进行了介绍。针对CAES发展中遇到的挑战,从电站建设、核心装备、标准体系、价格机制4个角度进行阐述,给出了推动CAES发展的建议,推动其向多元化、规模化、产业化方向发展,成为支撑我国“双碳”目标的关键技术。 展开更多
关键词 “双碳”目标 新能源发电 新型储能技术 压缩空气储能 工程现状 应用展望
下载PDF
上一页 1 2 6 下一页 到第
使用帮助 返回顶部